Tipharco Pharmaceutical JSC

Tipharco Pharmaceutical JSC maintains a conservative capital structure with a debt-to-equity ratio of 0.19 and a current ratio of 2.29, indicating strong short-term liquidity coverage. The company holds total assets of 279.6 billion VND against total liabilities of 80.7 billion VND, resulting in total equity of 198.9 billion VND. Long-term debt stands at 38.0 billion VND. Despite the strong current ratio, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting reliance on operating cash flows to service obligations.

Profitability metrics indicate modest returns, with a return on equity (ROE) of 6.44% and a return on assets (ROA) of 4.58%. The company generated net income of 12.8 billion VND on revenue of 317.0 billion VND, yielding a net margin of approximately 4.0%. Operating income was 15.0 billion VND, while gross profit stood at 66.4 billion VND. The valuation snapshot shows a price-to-earnings ratio of 0.04 and an EV/EBITDA of 2.57, suggesting the market values the equity at a significant discount to book value, with price-to-book and price-to-tangible-book ratios reported as 0.0.

Revenue concentration and segment details are not explicitly provided in the available data, preventing a detailed analysis of product mix or geographic exposure. The company’s financial snapshot does not break down revenue by segment or region, limiting the ability to assess concentration risk from disclosed operational data.

Growth trajectory analysis is constrained by the absence of historical period data in the input. Without multi-year revenue or net income trends, it is not possible to evaluate the company’s historical growth rate or momentum. The current financial snapshot provides a single-period view of performance, with revenue of 317.0 billion VND and net income of 12.8 billion VND.

Risk factors include medium liquidity risk and low dilution risk. A key flag indicates that net cash is negative after subtracting total debt, which may impact financial flexibility. The dilution risk is assessed as low, supported by the fact that basic and diluted shares outstanding are identical at 10,565,849 shares, indicating no immediate options or convertible securities impacting share count.

Recent observations include a failed analysis re-drive event for the ticker DTG.DE, which is a technical processing error rather than a fundamental business event. IR observations reference data for Daimler Truck Holding AG, including a market capitalization of USD 38.6 billion and 108,476 employees, which appears to be a data mismatch or error given the company name is Tipharco Pharmaceutical JSC. This discrepancy suggests potential data integrity issues in the source inputs, but no specific news events or filing observations related to Tipharco Pharmaceutical JSC are present.